AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37129110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recast therapy
Number of subjects: 33
Study 37129153 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM+PAC (ramucirumab and paclitaxel)
Number of subjects: 665
Study 37129153 — intervention group
Group type: COMPARATOR
Intervention: PL+PAC (placebo and paclitaxel)
Number of subjects: 665
Study 37129155 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance after XELOX chemotherapy
Number of subjects: 63
Study 37129155 — intervention group
Group type: COMPARATOR
Intervention: Observation after XELOX chemotherapy
Number of subjects: 63
Study 37129155 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance
Number of subjects: 63
Study 37129197 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor in combination with pembrolizumab
Number of subjects: 17
Study 37129384 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC901 (NeuroAiD II)
Number of subjects: 120
Study 37129384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 37129455 — intervention group
Group type: EXPERIMENTAL
Intervention: LCL161 plus oral topotecan
Number of subjects: 35
Study 37129475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal racism
Number of subjects: 542
Study 37129475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious racism
Number of subjects: 542
Study 37129493 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS version 2.1
Number of subjects: 454
Study 37129493 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI features including three-dimensional diameter, relative lesion volume, sphericity, and surface to volume ratio (SVR)
Number of subjects: 454
Study 37129584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon α-2b, starting dose of 250 μg, increasing to 350 μg at week 2 and 500 μg at week 4, with adjustments based on tolerability.
Number of subjects: 0
Study 37129687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 107
Study 37129687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 107
Study 37129691 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital healthcare rehabilitation group (DR group)
Number of subjects: 56
Study 37129691 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation group (CR group)
Number of subjects: 56
Study 37129691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DR and CR)
Number of subjects: 56
Study 37129892 — intervention group
Group type: EXPERIMENTAL
Intervention: QPS (Question Prompt Sheet)
Number of subjects: 130
Study 37129892 — intervention group
Group type: COMPARATOR
Intervention: GIS (General Information Sheet)
Number of subjects: 130
Study 37130017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles (∼2 years)
Number of subjects: 53
Study 37130044 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole treatment for 2 weeks at the dose level approved for ALS
Number of subjects: 32
Study 37130044 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole treatment
Number of subjects: 32
Study 37130076 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week pelvic floor muscle training (PFMT) program including instruction to perform the knack
Number of subjects: 69
Study 37130111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-related breathing disorders (SRBDs) severity
Number of subjects: 0
Study 37130111 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe SRBDs
Number of subjects: 0
Study 37130158 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation (LDLT)
Number of subjects: 81
Study 37130158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection
Number of subjects: 81
Study 37130158 — intervention group
Group type: COMPARATOR
Intervention: Control (continued systemic chemotherapy)
Number of subjects: 81
Study 37130297 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37130314 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 37130314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37130329 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for gastrointestinal cancer treatment
Number of subjects: 0
Study 37130329 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37130337 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER-MH intervention
Number of subjects: 50
Study 37130337 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study 37130608 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIQ collaborative quality improvement strategies including respiratory and nutritional care bundles, quality improvement team building, education, mentoring, and networking.
Number of subjects: 12
Study 37130608 — intervention group
Group type: COMPARATOR
Intervention: Control arm with current practices in the first year (all NICUs).
Number of subjects: 12
Study 37130657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 1202
Study 37130657 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 1202
Study 37130657 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines-directed care
Number of subjects: 1202
Study 37130657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) measures
Number of subjects: 1202
Study 37130658 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic coronary physiology (FFR)
Number of subjects: 150
Study 37130658 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) alone
Number of subjects: 150
Study 37130668 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition plan developed and delivered by a culturally congruent dietitian and health coach; FitBit to track steps
Number of subjects: 190
Study 37130668 — intervention group
Group type: COMPARATOR
Intervention: Usual care, plus weekly text messages to encourage walking and paper handouts
Number of subjects: 190
Study 37130668 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition plan
Number of subjects: 190
Study 37130670 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI combined with diagnostic guidance protocol
Number of subjects: 130
Study 37130670 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study 37130682 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 120
Study 37130682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FMT)
Number of subjects: 120
Study 37130681 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support (measured through structure and function variables)
Number of subjects: 359
Study 37130681 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM remission defined as glycated haemoglobin (HbA1c) <6.0% without medications
Number of subjects: 359
Study 37130685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid serological test (RST) for SARS-CoV-2 antibodies (OrientGene)
Number of subjects: 1073
Study 37130827 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Sedentary Behavior
Number of subjects: 273
Study 37130827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoccupational Sedentary Behavior
Number of subjects: 273
Study 37130827 — intervention group
Group type: EXPERIMENTAL
Intervention: All-domain Sedentary Behavior
Number of subjects: 273
Study 37131014 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + AC-T
Number of subjects: 70
Study 37131014 — intervention group
Group type: COMPARATOR
Intervention: Control (AC-T only)
Number of subjects: 70
Study 37131096 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models using single or serial concentrations of six different hs-cTn assays (ARTEMIS model)
Number of subjects: 2575
Study 37131096 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hs-cTn measurement using the ARTEMIS model
Number of subjects: 2575
Study 37131096 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models (ARTEMIS)
Number of subjects: 2575
Study 37131125 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney BEAM intervention
Number of subjects: 304
Study 37131125 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 304
Study 37131126 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 57
Study 37131126 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 57
Study 37131154 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard immunotherapy (IO) regimen administered every 3 months
Number of subjects: 646
Study 37131154 — intervention group
Group type: COMPARATOR
Intervention: Reduced intensity dose of IO administered every 3 months
Number of subjects: 646
Study 37131154 — intervention group
Group type: COMPARATOR
Intervention: Standard IO regimen
Number of subjects: 646
Study 37131180 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 110
Study 37131180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Number of subjects: 110
Study 37131180 — intervention group
Group type: COMPARATOR
Intervention: Neuroma transposition (active control)
Number of subjects: 110
Study 37131185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 37131191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine dose adjusted by height-based dosing algorithm
Number of subjects: 0
Study 37131191 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant bupivacaine dose
Number of subjects: 0
Study 37131217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Hyper-CVD plus inotuzumab with blinatumomab
Number of subjects: 110
Study 37131217 — intervention group
Group type: COMPARATOR
Intervention: Mini-Hyper-CVD plus inotuzumab without blinatumomab
Number of subjects: 110
Study 37131217 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 110
Study 37131217 — intervention group
Group type: COMPARATOR
Intervention: Original inotuzumab schedule
Number of subjects: 110
Study 37131217 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified inotuzumab schedule
Number of subjects: 110
Study 37131217 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving allogeneic SCT
Number of subjects: 110
Study 37131229 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized prescreening data collection
Number of subjects: 1029
Study 37131247 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 sessions of 'Goals in Focus' over the course of 6 months (n = 15)
Number of subjects: 30
Study 37131247 — intervention group
Group type: COMPARATOR
Intervention: 6-month wait-list control group (n = 15)
Number of subjects: 30
Study 37131265 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneous doses at 4-week intervals)
Number of subjects: 0
Study 37131531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IDA)
Number of subjects: 72
Study 37131531 — intervention group
Group type: COMPARATOR
Intervention: Sham IDA
Number of subjects: 72
Study 37131583 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Number of subjects: 0
Study 37131583 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) - Gamma-knife
Number of subjects: 0
Study 37131583 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) - LINAC
Number of subjects: 0
Study 37131643 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37131659 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with high antibody levels transfused early (symptom onset within 5 days)
Number of subjects: 179
Study 37131659 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 convalescent plasma (CCP) with low antibody levels or control plasma
Number of subjects: 179
Study 37131689 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Family-Centered Rounds
Number of subjects: 0
Study 37131689 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rounds)
Number of subjects: 0
Study 37131744 — intervention group
Group type: EXPERIMENTAL
Intervention: SVR III participants (140)
Number of subjects: 240
Study 37131744 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (100)
Number of subjects: 240
Study 37131755 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or condomless anal sex
Number of subjects: 70
Study 37131755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Number of subjects: 70
Study 37131755 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to a second-stage intervention (MI + CM or CM + MI)
Number of subjects: 70
Study 37131755 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue with assessments only
Number of subjects: 70
Study 37131861 — intervention group
Group type: EXPERIMENTAL
Intervention: PHH-1V booster vaccine
Number of subjects: 782
Study 37131861 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 booster vaccine
Number of subjects: 782
Study 37131861 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 782
Study 37132164 — intervention group
Group type: EXPERIMENTAL
Intervention: RN/CHW-led HCV intervention
Number of subjects: 10
Study 37132164 — intervention group
Group type: COMPARATOR
Intervention: cbSOC (clinic-based standard of care)
Number of subjects: 10
Study 37132182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 37132182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab combined with ipilimumab
Number of subjects: 0
Study 37132193 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD) alone
Number of subjects: 353
Study 37132193 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 353
Study 37132193 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 353
Study 37132193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipped node detection
Number of subjects: 353
Study 37132281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with gemcitabine 1000 mg/m² and nab-paclitaxel
Number of subjects: 19
Study 37132337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 344
Study 37132337 — intervention group
Group type: COMPARATOR
Intervention: EM-D or EM-P
Number of subjects: 344
Study 37132535 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative embolization
Number of subjects: 1010
Study 37132535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-embolization
Number of subjects: 1010
Study 37133249 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0
Study 37133249 — intervention group
Group type: COMPARATOR
Intervention: Historical standard of care (chemotherapy)
Number of subjects: 0
Study 37133402 — intervention group
Group type: EXPERIMENTAL
Intervention: Operatively treated periprosthetic proximal and distal femoral fractures
Number of subjects: 0
Study 37133429 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium bromide/olodaterol
Number of subjects: 0
Study 37133429 — intervention group
Group type: COMPARATOR
Intervention: fluticasone furoate/umeclidinium/vilanterol
Number of subjects: 0
Study 37133501 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt
Number of subjects: 60
Study 37133501 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60
Study 37133501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 60
Study 37133586 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count <100 cells per cubic millimeter
Number of subjects: 91
Study 37133586 — intervention group
Group type: COMPARATOR
Intervention: CD4 count 101 to 300 cells per cubic millimeter
Number of subjects: 91
Study 37133586 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk of death
Number of subjects: 91
Study 37133586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of cancer
Number of subjects: 91
Study 37133586 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to immunization against Covid-19
Number of subjects: 91
Study 37133586 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased susceptibility to diseases
Number of subjects: 91
Study 37133584 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary interruption of adjuvant endocrine therapy to attempt pregnancy
Number of subjects: 516
Study 37133584 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (external cohort of women who would have met entry criteria)
Number of subjects: 516
Study 37133585 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD-TPI plus bevacizumab (combination group)
Number of subjects: 246
Study 37133585 — intervention group
Group type: COMPARATOR
Intervention: FTD-TPI alone (FTD-TPI group)
Number of subjects: 246
Study 37133647 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (ACE inhibitors)
Number of subjects: 26851
Study 37133647 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (Angiotensin receptor blockers)
Number of subjects: 26851
Study 37133647 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (Mineralocorticoid receptor antagonists)
Number of subjects: 26851
Study 37133647 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD diagnosis
Number of subjects: 26851
Study 37133647 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in CKD diagnosis by 1 year
Number of subjects: 26851
Study 37133673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT): rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days (n=122)
Number of subjects: 243
Study 37133673 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole-containing hybrid therapy (HT): rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days (n=121)
Number of subjects: 243
Study 37133673 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in HDDT group
Number of subjects: 243
Study 37133673 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in HT group
Number of subjects: 243
Study 37133673 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee drinking habit in HDDT group
Number of subjects: 243
Study 37133673 — intervention group
Group type: COMPARATOR
Intervention: Coffee drinking habit in HT group
Number of subjects: 243
Study 37133829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target < 120 mm Hg)
Number of subjects: 7874
Study 37133829 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target < 140 mm Hg)
Number of subjects: 7874
Study 37133829 — intervention group
Group type: COMPARATOR
Intervention: Negative control (right bundle-branch block)
Number of subjects: 7874
Study 37133856 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast foam, 0.3%
Number of subjects: 226
Study 37133856 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 226
Study 37133909 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMPmyHospital app
Number of subjects: 0
Study 37133926 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based app-delivered mindfulness meditation
Number of subjects: 84
Study 37133926 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 84
Study 37134108 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe (ACAT inhibitor)
Number of subjects: 0
Study 37134130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-schedule rituximab infusion (500 mg)
Number of subjects: 135
Study 37134130 — intervention group
Group type: COMPARATOR
Intervention: Tailored-infusion regimen of rituximab
Number of subjects: 135
Study 37134130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml)
Number of subjects: 135
Study 37134230 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD (new powder dressing)
Number of subjects: 60
Study 37134230 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression dressing therapy
Number of subjects: 60
Study 37134294 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 64
Study 37134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide+PROSTVAC
Number of subjects: 64
Study 37137248 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-Related Potential (ERP) methodology
Number of subjects: 40
Study 37137248 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional magnetic resonance imaging (rsf/MRI) methodology
Number of subjects: 40
Study 37137248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing (N-P)
Number of subjects: 40
Study 37137248 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report Quality-Of-Life methodologies
Number of subjects: 40
Study 37137248 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 40
Study 37137304 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoID assay-guided chemotherapy
Number of subjects: 0
Study 37137304 — intervention group
Group type: COMPARATOR
Intervention: Physician-chosen chemotherapy
Number of subjects: 0
Study 37137378 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code I61
Number of subjects: 304
Study 37137378 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 code I63.x
Number of subjects: 304
Study 37137378 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 codes I60.1-7, I61, I62.9, I63
Number of subjects: 304
Study 37137388 — intervention group
Group type: EXPERIMENTAL
Intervention: TetraGraph
Number of subjects: 100